Mesenchymal stem cell therapy for liver disease: Current status and future perspectives

Young Woo Eom; Yongdae Yoon; Soon Koo Baik

doi:10.1097/MOG.0000000000000724

Mesenchymal stem cell therapy for liver disease: Current status and future perspectives

Young Woo Eom, Yongdae Yoon, Soon Koo Baik

Internal Medicine

Research output: Contribution to journal › Review article › peer-review

5 Citations (Scopus)

Abstract

Purpose of reviewLiver transplantation is the gold standard for the treatment of end-stage liver disease. However, a shortage of donor organs, high cost, and surgical complications limit the use of this treatment. Cellular therapies using hepatocytes, hematopoietic stem cells, bone marrow mononuclear cells, and mesenchymal stem cells (MSCs) are being investigated as alternative treatments to liver transplantation. The purpose of this review is to describe studies using MSC transplantation for liver diseases based on the reported literature and to discuss prospective research designed to improve the efficacy of MSC therapy.Recent findingsMSCs have several properties that show potential to regenerate injured tissues or organs, such as homing, transdifferentiation, immunosuppression, and cellular protective capacity. Additionally, MSCs can be noninvasively isolated from various tissues and expanded ex vivo in sufficient numbers for clinical evaluation.SummaryCurrently, there is no approved MSC therapy for the treatment of liver disease. However, MSC therapy is considered a promising alternative treatment for end-stage liver diseases and is reported to improve liver function safely with no side effects. Further robust preclinical and clinical studies will be needed to improve the therapeutic efficacy of MSC transplantation.

Original language	English
Pages (from-to)	216-223
Number of pages	8
Journal	Current Opinion in Gastroenterology
Volume	37
Issue number	3
DOIs	https://doi.org/10.1097/MOG.0000000000000724
Publication status	Published - 2021 May 1

Bibliographical note

Funding Information:
This work was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare (HI17C1365), and a Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2017R1D1A1A02019212) and funded by the Korean government, the Ministry of Education and the Medical Research Center Program (2017R1A5A2015369) from the Ministry of Science and ICT.

Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.

All Science Journal Classification (ASJC) codes

Gastroenterology

Access to Document

10.1097/MOG.0000000000000724

Cite this

@article{d488dcdc93464ab6b9a6c4b3aae6c483,

title = "Mesenchymal stem cell therapy for liver disease: Current status and future perspectives",

abstract = "Purpose of reviewLiver transplantation is the gold standard for the treatment of end-stage liver disease. However, a shortage of donor organs, high cost, and surgical complications limit the use of this treatment. Cellular therapies using hepatocytes, hematopoietic stem cells, bone marrow mononuclear cells, and mesenchymal stem cells (MSCs) are being investigated as alternative treatments to liver transplantation. The purpose of this review is to describe studies using MSC transplantation for liver diseases based on the reported literature and to discuss prospective research designed to improve the efficacy of MSC therapy.Recent findingsMSCs have several properties that show potential to regenerate injured tissues or organs, such as homing, transdifferentiation, immunosuppression, and cellular protective capacity. Additionally, MSCs can be noninvasively isolated from various tissues and expanded ex vivo in sufficient numbers for clinical evaluation.SummaryCurrently, there is no approved MSC therapy for the treatment of liver disease. However, MSC therapy is considered a promising alternative treatment for end-stage liver diseases and is reported to improve liver function safely with no side effects. Further robust preclinical and clinical studies will be needed to improve the therapeutic efficacy of MSC transplantation.",

author = "Eom, {Young Woo} and Yongdae Yoon and Baik, {Soon Koo}",

note = "Funding Information: This work was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare (HI17C1365), and a Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2017R1D1A1A02019212) and funded by the Korean government, the Ministry of Education and the Medical Research Center Program (2017R1A5A2015369) from the Ministry of Science and ICT. Publisher Copyright: {\textcopyright} 2021 Lippincott Williams and Wilkins. All rights reserved.",

year = "2021",

month = may,

day = "1",

doi = "10.1097/MOG.0000000000000724",

language = "English",

volume = "37",

pages = "216--223",

journal = "Current Opinion in Gastroenterology",

issn = "0267-1379",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Mesenchymal stem cell therapy for liver disease

T2 - Current status and future perspectives

AU - Eom, Young Woo

AU - Yoon, Yongdae

AU - Baik, Soon Koo

N1 - Funding Information: This work was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare (HI17C1365), and a Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2017R1D1A1A02019212) and funded by the Korean government, the Ministry of Education and the Medical Research Center Program (2017R1A5A2015369) from the Ministry of Science and ICT. Publisher Copyright: © 2021 Lippincott Williams and Wilkins. All rights reserved.

PY - 2021/5/1

Y1 - 2021/5/1

N2 - Purpose of reviewLiver transplantation is the gold standard for the treatment of end-stage liver disease. However, a shortage of donor organs, high cost, and surgical complications limit the use of this treatment. Cellular therapies using hepatocytes, hematopoietic stem cells, bone marrow mononuclear cells, and mesenchymal stem cells (MSCs) are being investigated as alternative treatments to liver transplantation. The purpose of this review is to describe studies using MSC transplantation for liver diseases based on the reported literature and to discuss prospective research designed to improve the efficacy of MSC therapy.Recent findingsMSCs have several properties that show potential to regenerate injured tissues or organs, such as homing, transdifferentiation, immunosuppression, and cellular protective capacity. Additionally, MSCs can be noninvasively isolated from various tissues and expanded ex vivo in sufficient numbers for clinical evaluation.SummaryCurrently, there is no approved MSC therapy for the treatment of liver disease. However, MSC therapy is considered a promising alternative treatment for end-stage liver diseases and is reported to improve liver function safely with no side effects. Further robust preclinical and clinical studies will be needed to improve the therapeutic efficacy of MSC transplantation.

AB - Purpose of reviewLiver transplantation is the gold standard for the treatment of end-stage liver disease. However, a shortage of donor organs, high cost, and surgical complications limit the use of this treatment. Cellular therapies using hepatocytes, hematopoietic stem cells, bone marrow mononuclear cells, and mesenchymal stem cells (MSCs) are being investigated as alternative treatments to liver transplantation. The purpose of this review is to describe studies using MSC transplantation for liver diseases based on the reported literature and to discuss prospective research designed to improve the efficacy of MSC therapy.Recent findingsMSCs have several properties that show potential to regenerate injured tissues or organs, such as homing, transdifferentiation, immunosuppression, and cellular protective capacity. Additionally, MSCs can be noninvasively isolated from various tissues and expanded ex vivo in sufficient numbers for clinical evaluation.SummaryCurrently, there is no approved MSC therapy for the treatment of liver disease. However, MSC therapy is considered a promising alternative treatment for end-stage liver diseases and is reported to improve liver function safely with no side effects. Further robust preclinical and clinical studies will be needed to improve the therapeutic efficacy of MSC transplantation.

UR - http://www.scopus.com/inward/record.url?scp=85103608060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103608060&partnerID=8YFLogxK

U2 - 10.1097/MOG.0000000000000724

DO - 10.1097/MOG.0000000000000724

M3 - Review article

C2 - 33769377

AN - SCOPUS:85103608060

SN - 0267-1379

VL - 37

SP - 216

EP - 223

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

IS - 3

ER -

Mesenchymal stem cell therapy for liver disease: Current status and future perspectives

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this